$APLS
Apellis Pharmaceuticals, Inc. Stock $apls

$apls Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000156459021008800 Filed on February 25, 2021

Income Statement

Concept	2020 Q4	2020 Q3	2020 Q2
Revenue	$250.0M	$646.0K	$0.00
YoY Change
Cost Of Revenue	$25.10M
YoY Change
Gross Profit	$225.0M
YoY Change
Gross Profit Margin	90.0%
Selling, General & Admin	$65.80M	$57.00M	$46.70M
YoY Change	139.27%	206.45%	264.84%
% of Gross Profit	29.24%
Research & Development	$29.00M	$93.21M	$87.09M
YoY Change	-63.06%	81.62%	71.79%
% of Gross Profit	12.89%
Depreciation & Amortization	$270.0K	$190.0K	$90.00K
YoY Change	200.0%	216.67%	80.0%
% of Gross Profit	0.12%
Operating Expenses	$94.80M	$130.2M	$115.5M
YoY Change	-10.48%	153.7%	127.83%
Operating Profit	$130.1M	-$129.6M	-$115.5M
YoY Change	-222.82%	85.21%	81.97%
Interest Expense	-$49.50M	-$6.100M	-$3.100M
YoY Change	587.5%	-1320.0%	-60.26%
% of Operating Profit	-38.04%
Other Income/Expense, Net	-$500.0K	-$16.00K	$5.000K
YoY Change	400.0%	-73.77%	-97.5%
Pretax Income	$80.10M	-$135.7M	-$118.6M
YoY Change	-170.76%	94.41%	66.81%
Income Tax	$1.800M
% Of Pretax Income	2.25%
Net Earnings	$78.27M	-$135.7M	-$118.6M
YoY Change	-169.13%	94.34%	66.85%
Net Earnings / Revenue	31.31%	-21006.19%
Basic Earnings Per Share	$1.03	-$1.79	-$1.57
Diluted Earnings Per Share	$0.93	-$1.79	-$1.57
COMMON SHARES
Basic Shares Outstanding			75.51M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$877.6M	$728.2M	$832.8M
YoY Change	149.32%	67.79%	188.07%
Cash & Equivalents	$565.8M	$415.6M	$317.3M
Short-Term Investments	$311.9M	$312.6M	$515.5M
Other Short-Term Assets	$26.88M	$14.20M	$21.00M
YoY Change	1954.89%	477.82%	525.75%
Inventory	$0.00
Prepaid Expenses	$11.40M
Receivables
Other Receivables
Total Short-Term Assets	$917.2M	$742.3M	$853.8M
YoY Change	145.83%	64.52%	176.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.803M	$25.10M	$15.40M
YoY Change	311.06%	1475.85%	970.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$18.86M	$900.0K	$900.0K
YoY Change	4797.4%	280.53%	332.96%
Total Long-Term Assets	$43.38M	$26.00M	$16.30M
YoY Change	168.59%	71.48%	96.59%
TOTAL ASSETS
Total Short-Term Assets	$917.2M	$742.3M	$853.8M
Total Long-Term Assets	$43.38M	$26.00M	$16.30M
Total Assets	$960.6M	$768.3M	$870.1M
YoY Change	146.78%	64.75%	174.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.477M	$11.10M	$9.900M
YoY Change	1.39%	-6.22%	-28.32%
Accrued Expenses	$111.9M	$60.77M	$45.40M
YoY Change	104.32%	99.68%	124.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.200M
YoY Change
Total Short-Term Liabilities	$128.3M	$75.30M	$58.00M
YoY Change	95.17%	68.94%	62.96%
LONG-TERM LIABILITIES
Long-Term Debt	$358.8M	$353.8M	$348.8M
YoY Change	151.61%	151.64%	5105.97%
Other Long-Term Liabilities	$268.9M	$233.5M	$231.2M
YoY Change	83.3%	93300.0%	92380.0%
Total Long-Term Liabilities	$627.7M	$587.3M	$580.0M
YoY Change	116.97%	234820.0%	231900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$128.3M	$75.30M	$58.00M
Total Long-Term Liabilities	$627.7M	$587.3M	$580.0M
Total Liabilities	$756.0M	$662.5M	$638.0M
YoY Change	112.95%	1378.06%	304.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$926.3M	-$1.005B
YoY Change	59.31%
Common Stock	$8.000K	$8.000K
YoY Change	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$204.6M	$105.8M	$232.1M
YoY Change
Total Liabilities & Shareholders Equity	$960.6M	$768.3M	$870.1M
YoY Change	146.78%	64.74%	174.74%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	$78.27M	-$135.7M	-$118.6M
YoY Change	-169.13%	94.34%	66.85%
Depreciation, Depletion And Amortization	$270.0K	$190.0K	$90.00K
YoY Change	200.0%	216.67%	80.0%
Cash From Operating Activities	$142.0M	-$99.83M	-$94.29M
YoY Change	-272.98%	86.28%	136.26%
INVESTING ACTIVITIES
Capital Expenditures	-$710.0K	-$3.740M	-$530.0K
YoY Change	373.33%	695.74%	178.95%
Acquisitions
YoY Change
Other Investing Activities	$620.0K	$202.5M	-$287.3M
YoY Change
Cash From Investing Activities	-$90.00K	$198.8M	-$287.8M
YoY Change	-40.0%	-42389.36%	151378.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.320M	920.0K	281.7M
YoY Change	2909.52%	-99.54%	587.67%
NET CHANGE
Cash From Operating Activities	142.0M	-99.83M	-94.29M
Cash From Investing Activities	-90.00K	198.8M	-287.8M
Cash From Financing Activities	6.320M	920.0K	281.7M
Net Change In Cash	148.2M	99.85M	-100.4M
YoY Change	-280.7%	-31.09%	-11777.91%
FREE CASH FLOW
Cash From Operating Activities	$142.0M	-$99.83M	-$94.29M
Capital Expenditures	-$710.0K	-$3.740M	-$530.0K
Free Cash Flow	$142.7M	-$96.09M	-$93.76M
YoY Change	-274.16%	80.89%	136.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1308000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11400000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1266000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	26878000
CY2020	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2018	us-gaap	Defined Contribution Plan Plan Name Extensible List DefinedContributionPlanPlanNameExtensibleList	apls:FourZeroOneKRetirementSavingsPlanMember
CY2019	us-gaap	Defined Contribution Plan Plan Name Extensible List DefinedContributionPlanPlanNameExtensibleList	apls:FourZeroOneKRetirementSavingsPlanMember
CY2020	us-gaap	Defined Contribution Plan Plan Name Extensible List DefinedContributionPlanPlanNameExtensibleList	apls:FourZeroOneKRetirementSavingsPlanMember
CY2020	apls	Defined Contribution Plan Eligibility Criteria Minimum Age Of Full Time Employees DefinedContributionPlanEligibilityCriteriaMinimumAgeOfFullTimeEmployees	P21Y
CY2020	apls	Net Operating Loss Carryforward Period NetOperatingLossCarryforwardPeriod	P3Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M28D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M19D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M13D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0032
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0142
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0268
CY2019Q4	us-gaap	Assets Current AssetsCurrent	373095000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17719000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6803000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1655000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18855000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	385000
CY2020Q4	us-gaap	Assets Assets	960569000
CY2019Q4	us-gaap	Assets Assets	389245000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8477000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8361000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	111935000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	54783000
CY2020Q4	apls	Development Derivative Liabilities Current DevelopmentDerivativeLiabilitiesCurrent	4230000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2609000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65753000
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	142567000
CY2019Q4	apls	Development Derivative Liabilities Noncurrent DevelopmentDerivativeLiabilitiesNoncurrent	134839000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11857000
CY2019Q4	us-gaap	Liabilities Liabilities	355016000
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63938000
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63938000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	6000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	615850000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-154000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	917192000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	34229000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-581473000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0176
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0256
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0299
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.844
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	250646000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.026
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.870
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.878
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.112
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.109
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	351985000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	311869000
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	19802000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14110000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1501000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	204557000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	960569000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	389245000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	299921000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	105286000
CY2020	apls	License Expense LicenseExpense	25050000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-103029000
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-14839000
CY2020	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	4164000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	220969000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	139401000
CY2020	us-gaap	Operating Expenses OperatingExpenses	464372000
CY2019	us-gaap	Operating Expenses OperatingExpenses	288015000
CY2018	us-gaap	Operating Expenses OperatingExpenses	127925000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-288015000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-127925000
CY2019	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	5108000
CY2018	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2961000
CY2020	apls	Interest Expense Nonoperating InterestExpenseNonoperating	29937000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-127502000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-123000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	160973000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3587000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	18902000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	2400000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	4732000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	2013000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7237000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10201000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	22489000
CY2020	apls	Adjustments To Additional Paid In Capital Purchase Of Capped Call Transactions And Associated Costs AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsAndAssociatedCosts	-43112000
CY2019	apls	Interest Expense Nonoperating InterestExpenseNonoperating	5285000
CY2018	apls	Interest Expense Nonoperating InterestExpenseNonoperating	2513000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-501000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-175000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-343029000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-304707000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-127502000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1845000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-344874000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-304707000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-127502000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-8000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	45000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-123000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	37000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-31000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-123000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-344837000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-304738000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-127625000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.59
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.90
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.34
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	75163000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62229000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54396000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	131195000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	728000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7733000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	109581000
CY2019	apls	Stock Issued During Period Value Stock Options Or Warrant Exercised StockIssuedDuringPeriodValueStockOptionsOrWarrantExercised	3129000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	72520000
CY2019	apls	Adjustments To Additional Paid In Capital Purchase Of Capped Call Transactions And Associated Costs AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsAndAssociatedCosts	-28380000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381423000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9418000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	120485000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	45376000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1575000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-8000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-344874000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	45000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	204557000
CY2020	us-gaap	Profit Loss ProfitLoss	-344874000
CY2019	us-gaap	Profit Loss ProfitLoss	-304707000
CY2018	us-gaap	Profit Loss ProfitLoss	-127502000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	45376000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	21144000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	7733000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	692178000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	388541000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	359000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1501000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-103029000
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-14839000
CY2020	apls	Non Cash Lease Expense NonCashLeaseExpense	222000
CY2019	apls	Non Cash Lease Expense NonCashLeaseExpense	356000
CY2020	us-gaap	Depreciation Depreciation	637000
CY2019	us-gaap	Depreciation Depreciation	240000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	52000
CY2018	apls	Amortization Of Discounts For Promissory Note AmortizationOfDiscountsForPromissoryNote	72000
CY2019	apls	Amortization Of Term Loan Facility Discounts AmortizationOfTermLoanFacilityDiscounts	104000
CY2018	apls	Amortization Of Term Loan Facility Discounts AmortizationOfTermLoanFacilityDiscounts	582000
CY2020	apls	Amortization Of Discounts For Convertible Notes Net Of Financing Costs AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts	15536000
CY2019	apls	Amortization Of Discounts For Convertible Notes Net Of Financing Costs AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts	2186000
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-8738000
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4531000
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	299000
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	26284000
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-287000
CY2018	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	19275000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	17860000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	323000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	309000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-54000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1641000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-978000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	55046000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	50454000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6587000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-158000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2148000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-160488000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-211135000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-131241000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5422000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1693000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	879067000
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	567500000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-316989000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1693000
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	18000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	381423000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	109581000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	131194000
CY2020	apls	Proceeds From Development Derivative Liability ProceedsFromDevelopmentDerivativeLiability	20000000
CY2019	apls	Proceeds From Development Derivative Liability ProceedsFromDevelopmentDerivativeLiability	120000000
CY2020	apls	Payments For Capped Call Transactions And Associated Costs PaymentsForCappedCallTransactionsAndAssociatedCosts	43112000
CY2019	apls	Payments For Capped Call Transactions And Associated Costs PaymentsForCappedCallTransactionsAndAssociatedCosts	28380000
CY2020	apls	Proceeds From Issuance Of Convertible Notes Net Of Issuance Costs ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCosts	322874000
CY2019	apls	Proceeds From Issuance Of Convertible Notes Net Of Issuance Costs ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCosts	212912000
CY2020	apls	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	9418000
CY2019	apls	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	3129000
CY2018	apls	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	727000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1575000
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7000000
CY2019	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	21701000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	131903000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-38000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	215060000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176268000
CY2020	apls	Equity Component Of Convertible Notes EquityComponentOfConvertibleNotes	120485000
CY2019	apls	Equity Component Of Convertible Notes EquityComponentOfConvertibleNotes	72520000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	351985000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	565779000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	351985000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	1266000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	567045000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	12929000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	987000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	175717000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	624000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	351985000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176268000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175644000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	567045000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Organization and Operations </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apellis Pharmaceuticals, Inc. (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated in September 2009 under the laws of the State of Delaware. The Company’s principal executive offices are located in Waltham, Massachusetts, effective January 1, 2020. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital and developing its product candidates. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”). Additionally, the Company is subject to risks arising from the Coronavirus Disease 2019 (COVID-19) pandemic, which could have adverse effects upon its business and operations, including on its ability to initiate, conduct and complete clinical trials, and could disrupt regulatory activities.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Agreement </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 27, 2020, the Company and its wholly-owned subsidiaries Apellis Switzerland GmbH and APL DEL Holdings, LLC entered into a Collaboration and License Agreement with Sobi, concerning the development and commercialization of pegcetacoplan and specified other structurally and functionally similar compstatin analogues or derivatives for use systemically or for local non-ophthalmological administration (collectively referred to as the “Licensed Products”). </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the collaboration agreement, the Company granted Sobi an exclusive (subject to certain retained rights of the Company), sublicensable license of certain patent rights and know-how to develop and commercialize Licensed Products in all countries outside of the United States. The Company retained the right to commercialize Licensed Products in the United States, and, subject to specified limitations, to develop Licensed Products worldwide for commercialization in the United States. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sobi paid the Company an upfront payment of $250.0 million in November 2020 and has agreed to pay up to an aggregate of $915.0 million upon the achievement of specified one-time regulatory and commercial milestone events, and to reimburse the Company for up to $80.0 million in development costs. The Company will also be entitled to receive tiered, double-digit royalties (ranging from high teens to high twenties) on sales of Licensed Products outside of the United States, subject to customary deductions and third-party payment obligations, until the latest to occur of: (i) expiration of the last-to-expire of specified licensed patent rights; (ii) expiration of regulatory exclusivity; and (iii) ten (10) years after the first commercial sale of the applicable Licensed Product, in each case on a Licensed Product-by-Licensed Product and country-by-country basis. Under the collaboration agreement, the Company remains responsible for its license fee obligations (including royalty obligations) to the University of Pennsylvania as a licensor of the Company and for its payment obligations to SFJ Pharmaceuticals. <span style="Background-color:#FFFFFF;color:#000000;">See note 11, License and Collaboration Agreements, for further discussion related to the Sobi collaboration agreemen</span>t. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Notes Offering</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 12, 2020, the Company completed a private offering of $300.0 million aggregate principal amount of 3.5% convertible senior notes due 2026 (the “2020 Convertible Notes”). The aggregate purchase price of the 2020 Convertible Notes was $328.9 million, which amount includes accrued interest from March 15, 2020 to, but not including, May 12, 2020. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net proceeds from the sale of the Convertible Notes were approximately $322.9 million after deducting the initial purchasers’ discounts and commissions and offering expenses paid by the company. The Company used $43.1 million of the net proceeds from the sale of the Convertible Notes to pay the cost of the capped call transactions described below. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="color:#000000;">The 2020 Convertible Notes form a single series with, and have the same terms as, the Company’s $220.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 issued on September 16, 2019, (the “2019 Convertible Notes”, and together with the 2020 Convertible Notes, the “Convertible Notes”), but have a different issue date, issue price, CUSIP number and different restrictions on transfer. The 2020 Convertible Notes were issued as additional notes under the indenture (the “Indenture”), dated as of September 16, 2019, by and between the Company and U.S. Bank National Association, as trustee (the “Trustee”), under which the 2019 Convertible Notes were issued. The 2020 Convertible Notes rank equal in right of payment to the 2019 Convertible Notes.</span> </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% per year payable </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">semiannually</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in arrears on March 15 and September 15 of each year, beginning on March 15, 2020.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Convertible Notes will mature on </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 15, 2026</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, unless converted</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> earlier</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">redeemed</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or repurchased in accordance with the terms</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Convertible Notes</span><span style="color:#000000;">. </span><span style="color:#000000;">See Note </span><span style="color:#000000;">6</span><span style="color:#000000;"> – Long-term Debt for additional information</span><span style="color:#000000;">.</span></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to year end, on January 6, 2021, the Company entered into separate, privately negotiated exchange agreements with certain holders of its 2019 Convertible Notes. Under the terms of these exchange agreements, the holders exchanged approximately $126.1 million in aggregate principal amount of 2019 Convertible Notes held by them for an aggregate of 3,906,869 shares of common stock. The exchange transactions closed on January 26, 2021. <span style="color:#212529;">As of the date of this Annual Report on Form 10-K, the Company holds the $126.1 million principal amounts of exchanged notes and such notes have not been cancelled.</span></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Capped Call Transactions </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 6, 2020, concurrently with the pricing of the 2020 Convertible Notes, the Company entered into capped call transactions with two counterparties. The capped call transactions are expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of the 2020 Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted 2020 Convertible Notes, as the case may be, in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which is initially $39.4625 (the conversion price of the 2020 Convertible Notes) and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of such 2020 Convertible Notes. <span style="font-weight:bold;font-style:italic;"> </span></p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Follow-on Public Offerings</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 13, 2020, the Company issued and sold 10,925,000 shares of its common stock at a price per share to the public of $37.00 in a follow-on public offering including an additional 1,425,000 shares of its common stock that were sold at the follow-on public offering price of $37.00 per share pursuant to the underwriters’ in full exercise of their option to purchase additional shares of common stock. The Company received net proceeds of approximately $381.4 million after deducting underwriting discounts and commissions of approximately $22.2 million and offering costs of $0.5 million for these transactions. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 11, 2019, the Company issued and sold 6,900,000 shares of its common stock at a price per share of $17.00 in a follow-on public offering. The Company received net proceeds of approximately $109.6 million after deducting underwriting discounts and commissions of approximately $7.0 million and offering costs of $0.7 million. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The accompanying consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of February 25, 2021, the date of issuance of these consolidated financial statements, the Company believes that its cash and cash equivalents and marketable securities as of December 31, 2020 of $877.6 million, will be sufficient to fund its operations and capital expenditures for at least the next twelve months from the date of issuance of these consolidated financial statements. The Company’s future viability beyond that point is dependent on its ability to raise additional capital to finance its operations.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to other life science companies in the development stage including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with FDA and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability. Management’s plans in order to meet its short-term and longer-term operating cash flow requirements include obtaining additional funding. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are uncertainties associated with the Company’s ability to (1) obtain additional debt or equity financing on terms that are favorable to the Company, (2) enter into collaborative agreements with strategic partners, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations, or is not able to obtain funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts and its business could be materially harmed. </p>
CY2020Q4	apls	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	877600000
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	27.85
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:2.28%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: development derivative liability, accrued expenses, prepaid expenses, convertible debt and taxes. </p>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are the only financial instruments that potentially subject the Company to concentrations of credit risk. <span style="color:#000000;">Cash and cash equivalents are held at financial institutions in the United States, Switzerland, Australia, Ireland and Germany. The Company is exposed to credit risk in the event of default by the financial institution to the extent that cash and cash equivalent balances recorded in the balance sheets are in excess of the amounts that are insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on its deposits since inception, and management believes that minimal credit risk exists with respect to these financial institutions. </span> </p>
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10032000
CY2018	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	14000
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9526000
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7291000
CY2019Q4	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	134839000
CY2020	apls	Minimum Payment Of Additional Funding Amount MinimumPaymentOfAdditionalFundingAmount	20000000
CY2019	apls	Minimum Payment Of Additional Funding Amount MinimumPaymentOfAdditionalFundingAmount	120000000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-103029000
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-14839000
CY2020Q4	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	257868000
CY2019Q4	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	134839000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	54783000
CY2020Q4	apls	Prepaid Research And Development Cost Current PrepaidResearchAndDevelopmentCostCurrent	8000000.0
CY2019Q4	apls	Prepaid Research And Development Cost Current PrepaidResearchAndDevelopmentCostCurrent	18100000
CY2020Q4	apls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	47879000
CY2019Q4	apls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	36449000
CY2020Q4	apls	Accrued License Fees Current AccruedLicenseFeesCurrent	25050000
CY2020Q4	apls	Accrued Payroll Liabilities Current AccruedPayrollLiabilitiesCurrent	22896000
CY2019Q4	apls	Accrued Payroll Liabilities Current AccruedPayrollLiabilitiesCurrent	11443000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	16110000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6891000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	111935000
CY2020	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company enters into lease agreements with terms generally ranging from 2-7 years. Some of the Company’s lease agreements include Company options to extend the lease on a month-to-month basis or for set periods for up to five years. Many leases also include options to terminate the leases within one year or per other contractual terms. Renewal and termination options were generally not included in the lease term for the Company’s existing operating leases.
CY2020	apls	Lessee Operating Lease Maximum Term Of Options To Terminate Lease LesseeOperatingLeaseMaximumTermOfOptionsToTerminateLease	P1Y
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17719000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14110000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	18902000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	14466000
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0774
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0819
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	4400000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4962000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4842000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4826000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4114000
CY2020Q4	apls	Lessee Operating Lease Liability Payments Due Year Five And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter	3745000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	37000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-31000
CY2020	apls	Contra Research And Development Expense ContraResearchAndDevelopmentExpense	43000000.0
CY2020	apls	Contra Research And Development Expense ContraResearchAndDevelopmentExpense	43000000.0
CY2020Q4	apls	Contra Research And Development Current ContraResearchAndDevelopmentCurrent	25000000.0
CY2020	apls	Contra Research And Development Long Term Assets ContraResearchAndDevelopmentLongTermAssets	18000000.0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1845000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-118839000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-297127000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-122900000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-224190000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7580000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4602000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-343029000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-304707000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-127502000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	57000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1788000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1845000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	240065000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-72036000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-63988000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-26775000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	22760000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Foreign EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign	-0.066
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-14107000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-16424000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.054
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-6398000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.699
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	90300000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.296
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	38157000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.299
CY2020	apls	Income Tax Reconciliation Intellectual Property Transfer IncomeTaxReconciliationIntellectualPropertyTransfer	-162000000
CY2020	apls	Effective Income Tax Rate Reconciliation Intellectual Property Transfer EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer	0.472
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	11696000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.034
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	6113000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.020
CY2018	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	6149000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.048
CY2020	apls	Tax Cuts And Jobs Act Of2017 Change In State Apportionment Tax Reform And Other TaxCutsAndJobsActOf2017ChangeInStateApportionmentTaxReformAndOther	93000
CY2019	apls	Tax Cuts And Jobs Act Of2017 Change In State Apportionment Tax Reform And Other TaxCutsAndJobsActOf2017ChangeInStateApportionmentTaxReformAndOther	-17000
CY2018	apls	Tax Cuts And Jobs Act Of2017 Change In State Apportionment Tax Reform And Other TaxCutsAndJobsActOf2017ChangeInStateApportionmentTaxReformAndOther	873000
CY2018	apls	Effective Income Tax Rate Reconciliation Change In State Apportionment Tax Reform And Other EffectiveIncomeTaxRateReconciliationChangeInStateApportionmentTaxReformAndOther	-0.007
CY2020	apls	Income Tax Reconciliation Permanent And Other Including Share Based Payments Excess Deductions IncomeTaxReconciliationPermanentAndOtherIncludingShareBasedPaymentsExcessDeductions	-1234000
CY2020	apls	Effective Income Tax Rate Change In Permanent And Other EffectiveIncomeTaxRateChangeInPermanentAndOther	0.003
CY2019	apls	Income Tax Reconciliation Permanent And Other Including Share Based Payments Excess Deductions IncomeTaxReconciliationPermanentAndOtherIncludingShareBasedPaymentsExcessDeductions	-3758000
CY2019	apls	Effective Income Tax Rate Change In Permanent And Other EffectiveIncomeTaxRateChangeInPermanentAndOther	0.012
CY2018	apls	Income Tax Reconciliation Permanent And Other Including Share Based Payments Excess Deductions IncomeTaxReconciliationPermanentAndOtherIncludingShareBasedPaymentsExcessDeductions	292000
CY2018	apls	Effective Income Tax Rate Change In Permanent And Other EffectiveIncomeTaxRateChangeInPermanentAndOther	-0.002
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1845000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.005
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	162011000
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	16000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11827000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6625000
CY2019Q4	apls	Deferred Tax Assets Contribution Carryforwards DeferredTaxAssetsContributionCarryforwards	41000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	122731000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	102623000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	24992000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	14476000
CY2020Q4	apls	Deferred Tax Assets Orphan Drug Credits DeferredTaxAssetsOrphanDrugCredits	14372000
CY2019Q4	apls	Deferred Tax Assets Orphan Drug Credits DeferredTaxAssetsOrphanDrugCredits	9380000
CY2020Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	68883000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4400000
CY2019Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	35875000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4520000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2259000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	207000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	171306000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	409543000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7733
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	166527000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	23000
CY2020Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	10473000
CY2019Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	11480000
CY2020Q4	apls	Deferred Tax Liabilities Section481 A Adjustment DeferredTaxLiabilitiesSection481AAdjustment	1935000
CY2019Q4	apls	Deferred Tax Liabilities Section481 A Adjustment DeferredTaxLiabilitiesSection481AAdjustment	2891000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	12431000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14371000
CY2020Q4	apls	Net Deferred Tax Assets Before Valuation Allowance NetDeferredTaxAssetsBeforeValuationAllowance	397112000
CY2019Q4	apls	Net Deferred Tax Assets Before Valuation Allowance NetDeferredTaxAssetsBeforeValuationAllowance	156935000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	397112000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	156935000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	240200000
CY2020Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.50
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Generally, the tax years 2017 through 2019 remain open and subject to examination by the major taxing jurisdictions to which the Company is subject.
CY2020Q4	apls	Estimated Termination Costs And Other Fees EstimatedTerminationCostsAndOtherFees	2800000
CY2020	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	13700000
CY2020	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	0
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45376
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21144
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P48M
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	Options granted to employees on or after December 5, 2013 generally vest in installments of (i) 25% at the one-year anniversary and (ii) in either 36 equal monthly or 12 equal quarterly installments beginning in the thirteenth month after the initial vesting commencement date (as defined) subject to the employee’s continuous service with the Company.
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10855000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.52
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2884000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	37.93
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1208000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.80
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	795000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	28.03
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11736000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.13
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6062000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.96
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2100000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2900000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	100100000
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	280290000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5674000
CY2020Q4	apls	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodAggregateIntrinsicValue	38000000.0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	27.52
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.31
CY2019Q4	apls	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodAggregateIntrinsicValue	15700000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.13
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M2D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5100000
CY2018Q4	apls	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodAggregateIntrinsicValue	5000000.0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	33600000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	12900000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-344874000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-304707000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-127502000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	75163000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62229000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54396000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.59
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.90
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.34
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-63476000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-69948000
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.79
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.93
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-48651000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25415000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10854000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7512000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-98786000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-115508000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-129552000
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	130120000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-168822000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-118617000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-135700000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	78265000
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.29
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.57
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.79
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.03
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.29
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.57
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-105940000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-50574000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-71090000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-69825000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-113218000
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.12
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.10
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.77

Files In Submission

Name	View Source	Status
0001564590-21-008800-index-headers.html	Edgar Link	pending
0001564590-21-008800-index.html	Edgar Link	pending
0001564590-21-008800.txt	Edgar Link	pending
0001564590-21-008800-xbrl.zip	Edgar Link	pending
apls-10k_20201231.htm	Edgar Link	pending
apls-10k_20201231_htm.xml	Edgar Link	completed
apls-20201231.xsd	Edgar Link	pending
apls-20201231_cal.xml	Edgar Link	unprocessable
apls-20201231_def.xml	Edgar Link	unprocessable
apls-20201231_lab.xml	Edgar Link	unprocessable
apls-20201231_pre.xml	Edgar Link	unprocessable
apls-ex1017_217.htm	Edgar Link	pending
apls-ex1025_88.htm	Edgar Link	pending
apls-ex1026_87.htm	Edgar Link	pending
apls-ex211_7.htm	Edgar Link	pending
apls-ex231_8.htm	Edgar Link	pending
apls-ex232_12.htm	Edgar Link	pending
apls-ex311_11.htm	Edgar Link	pending
apls-ex312_6.htm	Edgar Link	pending
apls-ex321_13.htm	Edgar Link	pending
apls-ex322_9.htm	Edgar Link	pending
apls-ex44_10.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gcro532wgjdp000001.jpg	Edgar Link	pending
gcro532wgjdp000002.jpg	Edgar Link	pending
ghsi5yfqsuki000001.jpg	Edgar Link	pending
ghsi5yfqsuki000002.jpg	Edgar Link	pending
ghsi5yfqsuki000003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APLS
Apellis Pharmaceuticals, Inc. Stock $apls

2020 Q4 Form 10-K Financial Statement

#000156459021008800 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APLS Apellis Pharmaceuticals, Inc. Stock $apls

2020 Q4 Form 10-K Financial Statement

#000156459021008800 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APLS
Apellis Pharmaceuticals, Inc. Stock $apls